| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 32.9 | 32.7 |
| Profit before tax | -1.7 | 2.5 |
| Net income | -2.5 | 1.9 |
| EPS (diluted, $ a share) | $-0.04 | $0.01 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +0.7% |
|---|---|
| Operating margin | -4.6% |
10-Q filed with the SEC, NASDAQ: GYRE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Gyre Therapeutics, Inc.: key numbers
- Share price
- $4.56Close, Nov 17
- Market cap
- $526M
- Shares outstanding
- 115.32MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Gyre Therapeutics, Inc.
All →Gyre Therapeutics Financial Results
Gyre Therapeutics reported Q3 2026 revenue of $32.9 million and affirmed its full-year 2026 revenue guidance of $100.5 million to $111.0 million. The company is preparing for a potential China NMPA decision on its liver fibrosis candidate F351 by early 2027 and is advancing several protein degrader programs into clinical trials.
- Term
- Q3 2026
“I am pleased with our execution in the third quarter, our first full quarter incorporating Cullgen's operations within Gyre Therapeutics. We are advancing our protein degrader pipeline toward first-in-human data and initiating new clinical programs next year. Meanwhile, after recently completing an onsite inspection by China’s National Medical Products Administration, or NMPA, we continue to prepare for the China NMPA decision on F351 for CHB-induced liver fibrosis, which we anticipate launching, if approved, sometime in the first half of 2027. Together, these programs are expected to drive our next phase of growth and demonstrate the strength of our unique business model, combining U.S. innovation with capital-efficient operations in China.”
Dr. Ying Luo, President and Chief Executive Officer
Gyre Therapeutics Executive Compensation
Gyre Therapeutics entered into new employment agreements with CEO Ying Luo, Ph.D., and CFO Thomas Eastling to continue their service. The agreements establish annual base salaries of $500,000 and $339,066 respectively, along with target bonuses and severance provisions including salary continuation and accelerated equity vesting upon certain termination events.